Darbepoetin alfa - Kirin/Amgen

Next Previous
Drug Profile

Darbepoetin alfa - Kirin/Amgen

Alternative Names: Aranesp; Darbepoetin-α; KRN-321; Nesp; Nespo; Novel erythropoiesis stimulating protein

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen; Kyowa Hakko Kirin
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase III Breast cancer

Most Recent Events

  • 21 Feb 2018 Amgen withdraws application for change in existing MAA to include treatment of Anaemia (in patients with myelodysblastic syndromes) in European Union
  • 02 Jan 2018 Amgen completes a phase II trial for Anaemia, before January 2018 (NCT00095264)
  • 19 Oct 2017 Amgen completes the START-CKD trial in Anaemia in Puerto Rico and USA (SC) (NCT01652872)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top